Andrea Palacios Navas*

Department of General Surgery, Hospital Clinica San Francisco, Ecuador

*Corresponding Author: Andrea Palacios Navas, Department of General Surgery, Hospital Clinica San Francisco, Ecuador.

Received: March 22, 2024; Published: April 01, 2024

Abstract

Gastric cancer ranks as the fifth most prevalent cancer globally. While its incidence is declining in the United States, it remains disproportionately high in certain Asian countries, notably Japan, South Korea, and Mongolia [1].

References

1. American Cancer Society. Stomach (Gastric) Cancer Key Statistics. American Cancer Society (2024).
2. Narita Y and Muro K. “Updated Immunotherapy for Gastric Cancer – PMC”. (2023).
3. Iikura Y., et al. “Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer”. Health Science Report (2022).
4. “Opdivo (nivolumab) dosing, indications, interactions, adverse effects, and more”. Medscape Reference (2017).

Citation

Citation: Andrea Palacios Navas. “Advancements in Immunotherapy for Gastric Cancer: Unveiling the Potential of PD-L1 Inhibitors". Acta Scientific Gastrointestinal Disorders 7.5 (2024): 01-02.

Copyright

Copyright: © 2024 Andrea Palacios Navas. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.